Is there a link between atrial fibrillation and certain bacterial infections?

Journal of Cardiovascular Medicine

Volumn 8, Issue 12, 2007, Pages 990-996

  Andrew, Peter ^a   Montenero, Annibale Sandro ^b  

^a aATLAS Medical Research Inc   (Canada)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Atrial fibrillation; C reactive protein; Chlamydia pneumoniae; Dysrhythmia; Helicobacter pylori; Infection; Inflammation

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; MACROLIDE; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE; ANTIARRHYTHMIC AGENT; ANTIINFECTIVE AGENT;

BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; HEART ARRHYTHMIA; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART MUSCLE; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HYPOTHESIS; INFLAMMATION; PATHOGENESIS; REVIEW; HELICOBACTER INFECTION; MICROBIOLOGY; RISK FACTOR;

ANTI-ARRHYTHMIA AGENTS; ANTI-BACTERIAL AGENTS; ATRIAL FIBRILLATION; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HEART ATRIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION; RISK FACTORS;

EID: 38449093074     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32801411e5     Document Type: Review

References (86)

1. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82:2N-9N.
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946-952.
3. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110:1042-1046.
4. Stoddard MF. Risk of thromboembolism in acute atrial fibrillation or atrial flutter. Echocardiography 2000; 17:393-405.
5. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001; 32:803-808.
6. Andrews M, Nelson BP. Atrial fibrillation. Mt Sinai J Med 2006; 73:482-492.
7. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92:1954-1968.
8. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation 1996; 94:2968-2974.
9. Schoonderwoerd BA, Van Gelder IC, Van Veldhuisen DJ, Van den Berg MP, Crijns HJ. Electrical and structural remodeling: role in the genesis and maintenance of atrial fibrillation. Prog Cardiovasc Dis 2005; 48:153-168.
10. Poret P, Mabo P, Deplace C, Leclercq C, Gras D, Marec BL, Daubert C. [Is isolated atrial fibrillation genetically determined? Apropos of a familial history]. Arch Mal Coeur Vaiss 1996; 89:1197-1203.
11. Brugada R. Is atrial fibrillation a genetic disease? J Cardiovasc Electrophysiol 2005; 16:553-556.
12. Wiesfeld AC, Hemels ME, Van Tintelen JP, Van den Berg MP, Van Veldhuisen DJ, Van Gelder IC. Genetic aspects of atrial fibrillation. Cardiovasc Res 2005; 67:414-418.
13. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339:659-666.
14. Khan R. Identifying and understanding the role of pulmonary vein activity in atrial fibrillation. Cardiovasc Res 2004; 64:387-394.
15. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104:174-180.
16. Everett THt, Olgin JE. Basic mechanisms of atrial fibrillation. Cardiol Clin 2004; 22:9-20.
17. Oral H. Mechanisms of atrial fibrillation: lessons from studies in patients. Prog Cardiovasc Dis 2005; 48:29-40.
18. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38:1231-1266.
19. Tsao HM, Chen SA. Evaluation of pulmonary vein stenosis after catheter ablation of atrial fibrillation. Card Electrophysiol Rev 2002; 6:397-400.
20. Pappone C. Pulmonary vein stenosis after catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2003; 14:165-167.
21. Humphries KH, Kerr CR, Steinbuch M, Dorian P. Limitations to antiarrhythmic drug use in patients with atrial fibrillation. CMAJ 2004; 171:741-745.
22. Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005; 21:1693-1699.
23. Marshall DA, Levy AR, Vidaillet H, Fenwick E, Slee A, Blackhouse G, et al. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med 2004; 141:653-661.
24. Zhou L, Keane D, Reed G, Ruskin J. Thromboembolic complications of cardiac radiofrequency catheter ablation: a review of the reported incidence, pathogenesis and current research directions. J Cardiovasc Electrophysiol 1999; 10:611-620.
25. Gonzalez MD. Rate control versus pulmonary vein isolation. Am J Geriatr Cardiol 2005; 14:26-30.
26. Nitta T. Surgery for atrial fibrillation. Ann Thorac Cardiovasc Surg 2005; 11:154-158.
27. Teng MP, Catherwood LE, Melby DP. Cost effectiveness of therapies for atrial fibrillation. A review. Pharmacoeconomics 2000; 18:317-333.
28. Weerasooriya R, Jais P, Le Heuzey JY, Scavee C, Choi KJ, Macle L, et al. Cost analysis of catheter ablation for paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 2003; 26:292-294.
29. Leonardi M, Bissett J. Prevention of atrial fibrillation. Curr Opin Cardiol 2005; 20:417-423.
30. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96:1180-1184.
31. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104:2886-2891.
32. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol 2001; 56:375-380.
33. Gaudino M, Andreotti F, Zamparelli R, Di Castelnuovo A, Nasso G, Burzotta F, et al. The -174G/C interleukin-6 polymorphisminfluences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 2003; 108 (Suppl 1):II195-II199.
34. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108:3006-3010.
35. Sata N, Hamada N, Horinouchi T, Amitani S, Yamashita T, Moriyama Y, Miyahara K. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J 2004; 45:441-445.
36. Anderson JL, Allen Maycock CA, Lappe DL, Crandall BG, Horne BD, Bair TL, et al. Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol 2004; 94:1255-1259.
37. Montenero AS, Mollichelli N, Zumbo F, Antonelli A, Dolci A, Barberis M, et al. Helicobacter pylori and atrial fibrillation: a possible pathogenic link. Heart 2005; 91:960-961.
38. Watanabe T, Takeishi Y, Hirono O, Itoh M, Matsui M, Nakamura K, et al. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels 2005; 20:45-49.
39. Wazni O, Martin DO, Marrouche NF, Shaaraoui M, Chung MK, Almahameed S, et al. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart 2005; 91:1303-1305.
40. Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A, Stakos D, Floros D, Papanas N, et al. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol 2006; 97:659-661.
41. Seguin P, Laviolle B, Maurice A, Leclercq C, Malledant Y. Atrial fibrillation in trauma patients requiring intensive care. Intensive Care Med 2006; 32:398-404.
42. Romano Carratelli C, Nuzzo I, Cozzolino D, Bentivoglio C, Paolillo R, Rizzo A. Relationship between Chlamydia pneumoniae infection, inflammatory markers, and coronary heart diseases. Int Immunopharmacol 2006; 6:848-853.
43. Lamm G, Auer J, Weber T, Berent R, Ng C, Eber B. Postoperative white blood cell count predicts atrial fibrillation after cardiac surgery. J Cardiothorac Vasc Anesth 2006; 20:51-56.
44. Fong IW. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ 2000; 163:49-56.
45. Larsen MM, Moern B, Fuller A, Andersen PL, Ostergaard LJ. Chlamydia pneumoniae and cardiovascular disease. Med J Aust 2002; 177:558-562.
46. Pellicano R, Oliaro E, Gandolfo N, Aruta E, Mangiardi L, Orzan F, et al. Ischemic cardiovascular disease and Helicobacter pylori. Where is the link? J Cardiovasc Surg (Torino) 2000; 41:829-833.
47. Tang RB, Dong JZ, Liu XP, Ma CS. Inflammation and atrial fibrillation: is Chlamydia pneumoniae a candidate pathogen of atrial fibrillation? Med Hypoth 2006; 67:462-466.
48. Franceschi F, Leo D, Fini L, Santoliquido A, Flore R, Tondi P, et al. Helicobacter pylori infection and ischaemic heart disease: an overview of the general literature. Dig Liver Dis 2005; 37:301-308.
49. Yamamoto M. Development of atherosclerosis and infectious agents. Intern Med 2003; 42:547-548.
50. Granstrom M, Tindberg Y, Blennow M. Seroepidemiology of Helicobacter pylori infection in a cohort of children monitored from 6 months to 11 years of age. J Clin Microbiol 1997; 35:468-470.
51. Logan RP, Walker MM. ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of Helicobacter pylori infection. BMJ 2001; 323:920-922.
52. Delaney B, Moayyedi P, Forman D. Helicobacter pylori infection. Clin Evid 2005; 6:518-534.
53. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347:1175-1186.
54. Goh KL. Helicobacter pylori and peptic ulcer disease - a causal link. Med J Malaysia 1997; 52:161-168.
55. Figueiredo C, Machado JC, Yamaoka Y. Pathogenesis of Helicobacter pylori infection. Helicobacter 2005; 10 (Suppl 1):14-20.
56. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 2000; 22:283-297.
57. Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995; 8:451-461.
58. Blasi F, Tarsia P, Arosio C, Fagetti L, Allegra L. Epidemiology of Chlamydia pneumoniae. Clin Microbiol Infect 1998; 4 (Suppl 4):S1-S6.
59. Monno R, Di Biase M, Costi A, de Nicolo T, Correale M, Bolognese P, Losacco G. [Chlamydia pneumoniae, atherosclerosis, and coronary disease]. Ital Heart J Suppl 2003; 4:383-397.
60. Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke 2003; 34:2518-2532.
61. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002; 288:2724-2731.
62. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312:1061-1065.
63. Bergman MP, Vandenbroucke-Grauls CM, Appelmelk BJ, D'Elios MM, Amedei A, Azzurri A, et al. The story so far: Helicobacter pylori and gastric autoimmunity. Int Rev Immunol 2005; 24:63-91.
64. Negrini R, Savio A, Appelmelk BJ. Autoantibodies to gastric mucosa in Helicobacter pylori infection. Helicobacter 1997; 2 (Suppl 1):S13-S16.
65. +-ATPase in the rat heart. Acta Physiol Scand 2003; 179:251-262.
66. + pump. Clin Sci (Lond) 1998; 95:3-17.
67. McDonough AA, Velotta JB, Schwinger RH, Philipson KD, Farley RA. The cardiac sodium pump: structure and function. Basic Res Cardiol 2002; 97 (Suppl 1):I19-I24.
68. Mussa FF, Chai H, Wang X, Yao Q, Lumsden AB, Chen C. Chlamydia pneumoniae and vascular disease: an update. J Vasc Surg 2006; 43:1301-1307.
69. Kudo S, Ouchi K, Asou A, Nagao K. [Demonstration of Chlamydophila pneumoniae and Chlamydia stress protein, HSP-60 in heart muscle tissue]. Kansenshogaku Zasshi 2001; 75:562-567.
70. Berger A. Autoimmune reaction links chlamydia to heart disease. BMJ 1999; 318:625B.
71. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352:1646-1654.
72. Berg HF, Maraha B, van der Zee A, Gielis SK, Roholl PJ, Scheffer GJ, et al. Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trial. J Clin Microbiol 2005; 43:1325-1329.
73. Krayenbuehl PA, Wiesli P, Maly FE, Vetter W, Schulthess G. Progression of peripheral arterial occlusive disease is associated with Chlamydia pneumoniae seropositivity and can be inhibited by antibiotic treatment. Atherosclerosis 2005; 179:103-110.
74. Wells BJ, Mainous AG III, Dickerson LM. Antibiotics for the secondary prevention of ischemic heart disease: a meta-analysis of randomized controlled trials. Arch Intern Med 2004; 164:2156-2161.
75. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002; 106:1219-1223.
76. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 2005; 293:2641-2647.
77. Candelli M, Nista EC, Carloni E, Pignataro G, Zocco MA, Cazzato A, et al. Treatment of H. pylori infection: a review. Curr Med Chem 2005; 12:375-384.
78. Hammerschlag MR. Chlamydia pneumoniae and the lung. Eur Resp J 2000; 16:1001-1007.
79. Pelletier E, Hernandez J, Clark M, Justason BFM. Medicare costs and resource use associated with atrial fibrillation patients. Heart Rhythm 2004; 1 (Suppl 57):175.
80. Stewart S. Epidemiology and economic impact of atrial fibrillation. J Cardiovasc Nurs 2004; 19:94-102.
81. Gooderham MJ, Bolli P, Fernandez PG. Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin. Ann Pharmacother 1999; 33:796-799.
82. Aebischer T, Schmitt A, Walduck AK, Meyer TF. Helicobacter pylori vaccine development: facing the challenge. Int J Med Microbiol 2005; 295:343-353.
83. Knaust A, Frosch M. Genome-based vaccines. Int J Med Microbiol 2004; 294:295-301.
84. Di Biase M, Troccoli R, Brunetti ND. Non-antiarrhythmic drugs for the prevention of cardiac arrhythmias. Ital Heart J 2005; 6:175-179.
85. Harris WS. Extending the cardiovascular benefits of omega-3 Fatty acids. Curr Atheroscler Rep 2005; 7:375-380.
86. Mazgalev TN. Drugs, ablation, denervation . . . and now fish oil: the global war on AF. J Cardiovasc Electrophysiol 2005; 16:1195-1199.